Record Information |
---|
Version | 2.0 |
---|
Created at | 2005-11-16 15:48:42 UTC |
---|
Updated at | 2021-10-07 20:39:22 UTC |
---|
NP-MRD ID | NP0000552 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Testosterone |
---|
Description | Testosterone is the primary male sex hormone and anabolic steroid from the androstane class of steroids. It is the most important androgen in potency and quantity for vertebrates. In humans, testosterone plays a key role in the development of male reproductive tissues such as testes and prostate, as well as promoting secondary sexual characteristics such as increased muscle and bone mass, and the growth of body hair. In addition, testosterone is involved in health and well-being, and the prevention of osteoporosis. Testosterone exerts its action through binding to and activation of the androgen receptor. In mammals, testosterone is metabolized mainly in the liver. Approximately 50% of testosterone is metabolized via conjugation into testosterone glucuronide and to a lesser extent testosterone sulfate by glucuronosyltransferases and sulfotransferases. An additional 40% of testosterone is metabolized in equal proportions into the 17-ketosteroids androsterone and etiocholanolone via the combined actions of 5alpha- and 5beta-reductases, 3alpha-hydroxysteroid dehydrogenase, and 17beta-HSD. Like other steroid hormones, testosterone is derived from cholesterol. The first step in the biosynthesis of testosterone involves the oxidative cleavage of the side-chain of cholesterol by the cholesterol side-chain cleavage enzyme (P450scc, CYP11A1) to give pregnenolone. In the next step, two additional carbon atoms are removed by the CYP17A1 (17alpha-hydroxylase/17,20-lyase) enzyme to yield a variety of C19 steroids. In addition, the 3beta-hydroxyl group is oxidized by 3beta-hydroxysteroid dehydrogenase to produce androstenedione. In the final and rate limiting step, the C17 keto group androstenedione is reduced by 17beta-hydroxysteroid hydrogenase to yield testosterone. Testosterone is synthesized and released by the Leydig cells in the testes that lie between the tubules and comprise less than 5% of the total testicular volume. Testosterone diffuses into the seminiferous tubules where it is essential for maintaining spermatogenesis. Some testosterone binds to an androgen-binding protein (ABP) that is produced by the Sertoli cells and is homologous to the sex-hormone binding globulin that transports testosterone in the general circulation. The ABP carries testosterone in the testicular fluid where it maintains the activity of the accessory sex glands and may also help to retain testosterone within the tubule and bind excess free hormone. Some testosterone is converted to estradiol by Sertoli cell-derived aromatase enzyme. Leydig cell steroidogenesis is controlled primarily by luteinizing hormone with negative feedback of testosterone on the hypothalamic-pituitary axis. The requirement of spermatogenesis for high local concentrations of testosterone means that loss of androgen production is likely to be accompanied by loss of spermatogenesis. Indeed, if testicular androgen production is inhibited by the administration of exogenous androgens then spermatogenesis ceases. This is the basis of using exogenous testosterone as a male contraceptive. The largest amounts of testosterone (>95%) are produced by the testes in men, while the adrenal glands account for most of the remainder. Testosterone is also synthesized in far smaller total quantities in women by the adrenal glands, thecal cells of the ovaries, and, during pregnancy, by the placenta. Testosterone levels fall by about 1% each year in men. Therefore, with increasing longevity and the aging of the population, the number of older men with testosterone deficiency will increase substantially over the next several decades. Serum testosterone levels decrease progressively in aging men, but the rate and magnitude of decrease vary considerably. Approximately 1% of healthy young men have total serum testosterone levels below normal; in contrast, approximately 20% of healthy men over age 60 years have serum testosterone levels below normal. (PMID: 17904450 , 17875487 ). |
---|
Structure | [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1 |
---|
Synonyms | Value | Source |
---|
17beta-Hydroxy-4-androsten-3-one | ChEBI | 4-Androsten-17beta-ol-3-one | ChEBI | Androderm | ChEBI | Testosteron | ChEBI | Testosterona | ChEBI | Testosteronum | ChEBI | Androgel | Kegg | Axiron | Kegg | Striant | Kegg | Testim | Kegg | 17b-Hydroxy-4-androsten-3-one | Generator | 17Β-hydroxy-4-androsten-3-one | Generator | 4-Androsten-17b-ol-3-one | Generator | 4-Androsten-17β-ol-3-one | Generator | (+)-Testosterone | HMDB | (+-)-8-Iso-testosterone | HMDB | (+-)-Retrotestosterone | HMDB | (+-)-Testosterone | HMDB | (17b)-17-Hydroxy-androst-4-en-3-one | HMDB | 13-Iso-testosterone | HMDB | 17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one | HMDB | 17-Hydroxy-androst-4-en-3-one | HMDB | 17-Hydroxy-D4-androsten-3-one | HMDB | 17a-Hydroxy-(13a)-androst-4-en-3-one | HMDB | 17a-Hydroxy-13a-androst-4-en-3-one | HMDB | 17a-Hydroxy-14b-androst-4-en-3-one | HMDB | 17a-Hydroxy-androst-4-en-3-one | HMDB | 17b-Hydroxy-(10a)-androst-4-en-3-one | HMDB | 17b-Hydroxy-(13a)-androst-4-en-3-one | HMDB | 17b-Hydroxy-(8a)-androst-4-en-3-one | HMDB | 17b-Hydroxy-(8a,10a)-androst-4-en-3-one | HMDB | 17b-Hydroxy-(9b)-androst-4-en-3-one | HMDB | 17b-Hydroxy-(9b,10a)-androst-4-en-3-one | HMDB | 17b-Hydroxy-13a-androst-4-en-3-one | HMDB | 17b-Hydroxy-8a-androst-4-en-3-one | HMDB | 17b-Hydroxy-androst-4-en-3-ON | HMDB | 17b-Hydroxy-androst-4-en-3-one | HMDB | 17b-Hydroxy-D4-androsten-3-one | HMDB | 17b-Hydroxyandrost-4-en-3-one | HMDB | 17b-Hydroxyandrost-4-ene-3-one | HMDB | 17b-Testosterone | HMDB | 4-Androsten-3-one-17b-ol | HMDB | 8-Iso-testosterone | HMDB | 9b,10a-Testosterone | HMDB | 9b-Testosterone | HMDB | Androlin | HMDB | Andronaq | HMDB | Andropatch | HMDB | Androst-4-en-17b-ol-3-one | HMDB | Androst-4-ene-17b-ol-3-one | HMDB | Andrusol | HMDB | Cristerona T | HMDB | D4-Androsten-17b-ol-3-one | HMDB | Epitestosteron | HMDB | Geno-cristaux gremy | HMDB | Homosteron | HMDB | Homosterone | HMDB | Lumitestosteron | HMDB | Mertestate | HMDB | Neotestis | HMDB | Oreton | HMDB | Orquisteron | HMDB | Perandren | HMDB | Percutacrine androgenique | HMDB | Primotest | HMDB | Primoteston | HMDB | rac-17b-Hydroxy-(13a)androst-4-en-3-one | HMDB | rac-17b-Hydroxy-(8a)-androst-4-en-3-one | HMDB | rac-17b-Hydroxy-(9b,10a)androst-4-en-3-one | HMDB | rac-17b-Hydroxy-androst-4-en-3-one | HMDB | Relibra | HMDB | Retrotestosterone | HMDB | Sustanon | HMDB | Sustanone | HMDB | Sustason 250 | HMDB | Synandrol F | HMDB | Teslen | HMDB | Testandrone | HMDB | Testiculosterone | HMDB | Testobase | HMDB | Testoderm | HMDB | Testogel | HMDB | Testolent | HMDB | Testolin | HMDB | Testopropon | HMDB | Testosteroid | HMDB | Testoviron schering | HMDB | Testoviron T | HMDB | Testro aq | HMDB | Testrone | HMDB | Testryl | HMDB | Tostrelle | HMDB | Tostrex | HMDB | Viatrel | HMDB | Virormone | HMDB | Virosterone | HMDB | Androtop | HMDB | CEPA brand OF testosterone | HMDB | Histerone | HMDB | SmithKline beecham brand OF testosterone | HMDB | Solvay brand OF testosterone | HMDB | Sterotate | HMDB | 17-beta-Hydroxy-8 alpha-4-androsten-3-one | HMDB | AstraZeneca brand OF testosterone | HMDB | Bartor brand OF testosterone | HMDB | Dr. kade brand OF testosterone | HMDB | Ferring brand OF testosterone | HMDB | Hauck brand OF testosterone | HMDB | Pasadena brand OF testosterone | HMDB | Testosterone sulfate | HMDB | Ulmer brand OF testosterone | HMDB | Unimed brand OF testosterone | HMDB | Watson brand OF testosterone | HMDB | 17-beta-Hydroxy-4-androsten-3-one | HMDB | 8 Isotestosterone | HMDB | 8-Isotestosterone | HMDB | Auxilium pharmaceuticals inc. brand OF testosterone | HMDB | Faulding brand OF testosterone | HMDB | Paladin brand OF testosterone | HMDB | Schering brand OF testosterone | HMDB | 17 beta Hydroxy 4 androsten 3 one | HMDB | 17 beta Hydroxy 8 alpha 4 androsten 3 one | HMDB | GlaxoSmithKline brand OF testosterone | HMDB | Ortho brand OF testosterone | HMDB | Testopel | HMDB |
|
---|
Chemical Formula | C19H28O2 |
---|
Average Mass | 288.4244 Da |
---|
Monoisotopic Mass | 288.20893 Da |
---|
IUPAC Name | (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one |
---|
Traditional Name | (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one |
---|
CAS Registry Number | 58-22-0 |
---|
SMILES | [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
---|
InChI Identifier | InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1 |
---|
InChI Key | MUMGGOZAMZWBJJ-DYKIIFRCSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 500 MHz, CDCl3, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, CDCl3, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Androstane steroids |
---|
Direct Parent | Androgens and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Androgen-skeleton
- 3-oxo-delta-4-steroid
- 3-oxosteroid
- Hydroxysteroid
- Oxosteroid
- 17-hydroxysteroid
- Delta-4-steroid
- Cyclohexenone
- Cyclic alcohol
- Secondary alcohol
- Ketone
- Cyclic ketone
- Organooxygen compound
- Alcohol
- Carbonyl group
- Organic oxygen compound
- Hydrocarbon derivative
- Organic oxide
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | 155 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.023 mg/mL | Not Available | LogP | 3.32 | Hansch CH, Leo A and Hoekman DH. "Exploring QSAR: Hydrophobic, Electronic, and Steric Constraints. Volume 1" ACS Publications (1995). |
|
---|
Predicted Properties | |
---|
General References | - Kim YS, Zhang H, Kim HY: Profiling neurosteroids in cerebrospinal fluids and plasma by gas chromatography/electron capture negative chemical ionization mass spectrometry. Anal Biochem. 2000 Jan 15;277(2):187-95. [PubMed:10625505 ]
- Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Pizzorni C, Paolino S, Seriolo B, Felli L, Straub RH: Anti-TNF and sex hormones. Ann N Y Acad Sci. 2006 Jun;1069:391-400. [PubMed:16855166 ]
- Schwarz S, Pohl P: Steroid hormones and steroid hormone binding globulins in cerebrospinal fluid studied in individuals with intact and with disturbed blood-cerebrospinal fluid barrier. Neuroendocrinology. 1992 Feb;55(2):174-82. [PubMed:1620285 ]
- Schaap LA, Pluijm SM, Smit JH, van Schoor NM, Visser M, Gooren LJ, Lips P: The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol (Oxf). 2005 Aug;63(2):152-60. [PubMed:16060908 ]
- Archer JS, Love-Geffen TE, Herbst-Damm KL, Swinney DA, Chang JR: Effect of estradiol versus estradiol and testosterone on brain-activation patterns in postmenopausal women. Menopause. 2006 May-Jun;13(3):528-37. [PubMed:16735951 ]
- Handelsman DJ: Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J Clin Endocrinol Metab. 2006 May;91(5):1646-53. Epub 2006 Feb 14. [PubMed:16478815 ]
- Duschek EJ, Gooren LJ, Netelenbos C: Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. Maturitas. 2005 Jul 16;51(3):286-93. [PubMed:15978972 ]
- Huang I, Jones J, Khorram O: Human seminal plasma nitric oxide: correlation with sperm morphology and testosterone. Med Sci Monit. 2006 Mar;12(3):CR103-6. Epub 2006 Feb 23. [PubMed:16501419 ]
- Hussein A, Ozgok Y, Ross L, Niederberger C: Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Androl. 2005 Nov-Dec;26(6):787-91; discussion 792-3. [PubMed:16291975 ]
- Ahtiainen JP, Pakarinen A, Alen M, Kraemer WJ, Hakkinen K: Short vs. long rest period between the sets in hypertrophic resistance training: influence on muscle strength, size, and hormonal adaptations in trained men. J Strength Cond Res. 2005 Aug;19(3):572-82. [PubMed:16095405 ]
- Landman AD, Sanford LM, Howland BE, Dawes C, Pritchard ET: Testosterone in human saliva. Experientia. 1976;32(7):940-1. [PubMed:954994 ]
- Knickmeyer RC, Wheelwright S, Taylor K, Raggatt P, Hackett G, Baron-Cohen S: Gender-typed play and amniotic testosterone. Dev Psychol. 2005 May;41(3):517-28. [PubMed:15910159 ]
- Fejes I, Koloszar S, Szollosi J, Zavaczki Z, Pal A: Is semen quality affected by male body fat distribution? Andrologia. 2005 Oct;37(5):155-9. [PubMed:16266392 ]
- Jarow JP, Zirkin BR: The androgen microenvironment of the human testis and hormonal control of spermatogenesis. Ann N Y Acad Sci. 2005 Dec;1061:208-20. [PubMed:16467270 ]
- Rovensky J, Radikova Z, Imrich R, Greguska O, Vigas M, Macho L: Gonadal and adrenal steroid hormones in plasma and synovial fluid of patients with rheumatoid arthritis. Endocr Regul. 2004 Dec;38(4):143-9. [PubMed:15841793 ]
- Klimek M, Pabian W, Tomaszewska B, Kolodziejczyk J: Levels of plasma ACTH in men from infertile couples. Neuro Endocrinol Lett. 2005 Aug;26(4):347-50. [PubMed:16136011 ]
- Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR: Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006 Aug 14-28;166(15):1660-5. [PubMed:16908801 ]
- Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun;91(6):1995-2010. Epub 2006 May 23. [PubMed:16720669 ]
- Jarow JP, Wright WW, Brown TR, Yan X, Zirkin BR: Bioactivity of androgens within the testes and serum of normal men. J Androl. 2005 May-Jun;26(3):343-8. [PubMed:15867001 ]
- Bridger T, MacDonald S, Baltzer F, Rodd C: Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2006 Mar;160(3):241-6. [PubMed:16520442 ]
- Kazi M, Geraci SA, Koch CA: Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am J Med. 2007 Oct;120(10):835-40. [PubMed:17904450 ]
- Krone N, Hanley NA, Arlt W: Age-specific changes in sex steroid biosynthesis and sex development. Best Pract Res Clin Endocrinol Metab. 2007 Sep;21(3):393-401. [PubMed:17875487 ]
- Authors unspecified: Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990 Oct 20;336(8721):955-9. [PubMed:1977002 ]
- Hoberman JM, Yesalis CE: The history of synthetic testosterone. Sci Am. 1995 Feb;272(2):76-81. [PubMed:7817189 ]
- Freeman ER, Bloom DA, McGuire EJ: A brief history of testosterone. J Urol. 2001 Feb;165(2):371-3. [PubMed:11176375 ]
|
---|